Pope Michael Ross - 23 Feb 2022 Form 4 Insider Report for Novo Integrated Sciences, Inc. (NVOS)

Reporting relationship: Director
Issuer ticker: NVOS
Reported as of: 23 Feb 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Feb 2022, 15:05:22 UTC
Prior SEC filing: 24 Feb 2022
Next SEC filing: 13 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Christopher David, as Attorney-in-Fact for Michael Pope

Key filing fact

Pope Michael Ross filed Form 4 for Novo Integrated Sciences, Inc. (NVOS) on 24 Feb 2022.

Key facts

This page summarizes Pope Michael Ross's Form 4 filing for Novo Integrated Sciences, Inc. (NVOS).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 24 Feb 2022, 15:05.

Change

Previous filing in this sequence was filed on 24 Feb 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NVOS transaction Derivative

Stock option(right to buy)

Award

Transaction value: $0
Shares: +93,995
Change %
Price: $0.000000
Shares after: 93,995
Date: 23 Feb 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 93,995
Exercise price: $1.33
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents a grant approved by the issuer's Board of Directors. The stock option vests, and becomes exercisable, with respect to 7,833 shares each month, beginning on the date of grant, until December 23, 2022 and with respect to 7,832 shares on January 23, 2023.